| I-31 Maddlie Bardol Population pharmacokinetics of fentanyl in very preterm infants Wednesday 09:50-11:15 |
| I-79 Sinziana Cristea Untangling maturation functions for kidney transporters using a combined population pharmacokinetics and physiology-based pharmacokinetics approach Wednesday 09:50-11:15 |
| I-80 Salvatore D'Agate Population Pharmacokinetics and Effect of Variable Renal Function on the Exposure to Aciclovir in Term and Pre-term Neonates Wednesday 09:50-11:15 |
| II-08 Jean Lavigne Population Pharmacokinetics of Piperacillin-Tazobactam Extended Infusions in Paediatric Population Wednesday 15:10-16:40 |
| II-47 Danica Michalickova Pharmacokinetics of phenobarbital in neonates on extracorporeal membrane oxygenation Wednesday 15:10-16:40 |
| II-74 Soumya Perinparajah Pharmacodynamics of rituximab on B cells in paediatric post-HSCT patients with EBV Wednesday 15:10-16:40 |
| III-01 Clémence Rigaux An approach for reducing the sample sizes of pediatric trials in Type 2 Diabetes Mellitus: longitudinal analysis versus standard analyses Thursday 09:55-11:20 |
| III-11 Louis Sandra A population pharmacokinetic model for propofol in (pre)term neonates and infants independently accounting for size, gestational age (GA) and postnatal age (PNA). Thursday 09:55-11:20 |
| III-23 Erik Sjögren A PBPK Framework to Predict Drug Exposure in Malnourished Children Thursday 09:55-11:20 |
| III-25 Elena Soto Population Pharmacokinetic (PopPK) Modelling and Simulation of Pregabalin to Support Dose Recommendation in Paediatric Patients 1 month to <4 years of Age with Partial Onset Seizures (POS) Thursday 09:55-11:20 |
| III-27 Viktoria Stachanow Does dried blood spot data enrich our understanding of hydrocortisone pharmacokinetics in paediatric patients with adrenal insufficiency? Thursday 09:55-11:20 |
| III-49 Parth Upadhyay Exploring the Relationship Between Midazolam Concentrations And Level Of Sedation In Critically-Ill Mechanically Ventilated Children Using Markov Modelling Thursday 09:55-11:20 |
| III-51 Pavan Vaddady Application of Bayesian Methodology to Inform Imipenem/Relebactam Pediatric Study Design Thursday 09:55-11:20 |
| III-55 Louvina van der Laan Pharmacokinetics and drug-drug interactions of lamivudine and abacavir administered with antituberculosis drugs in HIV-infected children with multidrug-resistant tuberculosis Thursday 09:55-11:20 |
| III-57 Tamara van Donge Methadone dosing strategies in preterm neonates can be simplified Thursday 09:55-11:20 |
| IV-09 Aline Engbers Postnatal age, gestational age and small for gestational age drive the pharmacokinetics of ibuprofen enantiomers in very preterm neonates with patent ductus arteriosus Thursday 15:25-16:50 |
| IV-10 Muhammad Faisal Simultaneous semi-mechanistic population pharmacokinetic analysis of enalapril and enalaprilat in serum and urine following the administration of child appropriate oro-dispersible mini-tablets. Thursday 15:25-16:50 |
| IV-31 Ferran Gonzalez Pharmacokinetic model development for total and free vancomycin in critically ill children Thursday 15:25-16:50 |
| IV-35 Iztok Grabnar Oxcarbazepine and its active metabolite 10-monohydroxycarbamazepine clearance maturation in paediatric patients with epilepsy Thursday 15:25-16:50 |
| IV-42 Lutz Harnisch Dose Selection Process for Younger Children Participating in a Phase 3 Study to Evaluate the Efficacy and Safety of Rivipansel (GMI-1070) in the Treatment of Vaso-occlusive Crisis in Hospitalized Patients With Sickle Cell Disease Thursday 15:25-16:50 |
| IV-43 Paul Healy PKPD bridging and extrapolation of efficacy for the use of gabapentin and tramadol in paediatric chronic pain. Thursday 15:25-16:50 |
